Greenwich LifeSciences, Inc.
NASDAQ:GLSI
Overview | Financials
Company Name | Greenwich LifeSciences, Inc. |
Symbol | GLSI |
Currency | USD |
Price | 11.23 |
Market Cap | 147,614,981 |
Dividend Yield | 0% |
52-week-range | 8 - 21.44 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Mr. Snehal S. Patel |
Website | https://greenwichlifesciences.com |
An error occurred while fetching data.
About Greenwich LifeSciences, Inc.
Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent breast cancer recurrences in patients who have previously undergone
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD